黑料吃瓜群网

Promising results from a phase 3 trial of the oral medication Baricitinib for patients with Systemic Lupus Erythematosus (SLE) have been聽published in . Baricitinib is commonly used for the treatment of rheumatoid arthritis, atopic dermatitis聽and alopecia areata.

A considerable body of evidence supported the role of pathways targeted by Baricitinib in the pathogenesis of lupus, including a phase 2 study, which showed daily oral Baricitinib was superior to placebo in improving SLE activity 鈥斅爌articularly resolving rash and joint manifestations.

The current study was positive, but a negative companion study means that the benefit of Baricitinib for the treatment of patients with moderately to severe active SLE is unclear. The development program for Baricitinib in SLE has therefore been discontinued.

Study author Professor Eric Morand, Head of the School of Clinical Sciences at Monash University and an international expert in lupus, said, 鈥淚n many ways, this has sent us back to the drawing board, but all results help us know where to go from here.

鈥淲e are determined to find effective treatments for all autoimmune diseases, including SLE, because people who have these diseases experience significant challenges to quality of life, and in many cases, shortened life expectancy. It is not acceptable.鈥�

To this end,聽Morand led a of a different drug 鈥� deucvravacitinib 鈥� that shows promise, and Phase 3 trials are planned.

鈥淎s lupus is a disease where no two patients are alike, measurement of treatment effects is complex and complicated. Monash is leading a global project to generate new and better validated clinical trial measures and continues the quest for relief for patients,鈥� Morand said.

Image credit: iStock.com/Maks_Lab